ReviewRheumatology (Oxford, England)2019
Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
Review in Rheumatology (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Clinical Characteristics and Management of Immune Checkpoint Inhibitor-Associated Sicca Syndrome.Cancers · 2026Article
- Pembrolizumab-Induced Myositis: Diagnostic and Therapeutic Challenges From Two Case Reports and a Narrative Review.Cancer reports (Hoboken, N.J.) · 2026Review
- Immune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management.Journal of thrombosis and thrombolysis · 2025Review
- Immune checkpoint inhibitor-related arthritis and oral disorders: shared pathophysiology and clinical implications for rheumatology and oral health.Cancer cell international · 2025Review
- Article
- Review
- Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Overview of Therapies and a Personalized Approach to Optimized Combined Therapy.European journal of rheumatology · 2024Article
- IgA vasculitis induced by carboplatin + nab-paclitaxel + pembrolizumab in a patient with advanced lung squamous cell carcinoma: a case report.Frontiers in immunology · 2024Article
- Adverse event costs associated with first-line therapy for advanced non-small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors.Journal of managed care & specialty pharmacy · 2023Article
- Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events.Journal for immunotherapy of cancer · 2023Observational
- Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience.Frontiers in oncology · 2023Article
- Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis.Arthritis research & therapy · 2022Article
- Rheumatological Adverse Events Following Immunotherapy for Cancer.Medicina (Kaunas, Lithuania) · 2022Article
- [Myofasciitis under nivolumab treatment].Zeitschrift fur Rheumatologie · 2021Article
- The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma.Biomedicines · 2021Review
- Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy.Frontiers in medicine · 2021Review
- Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review.Future science OA · 2020Article
- [Clinical management of rheumatic immune-related adverse events : Recognize and treat rheumatological side effects of checkpoint inhibition].Zeitschrift fur Rheumatologie · 2020Review
- Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside.International journal of molecular sciences · 2020Review
- [Side effects of novel cancer immunotherapies].Der nephrologe · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since immune checkpoint inhibitors became the standard of care for an increasing number of indications, more patients have been exposed to these drugs and physicians are more challenged with the management of a unique spectrum of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors. Those irAEs of autoimmune or autoinflammatory origin, or both, can involve any organ or tissue, but most commonly affect the dermatological, gastrointestinal and endocrine systems. Rheumatic/systemic irAEs seem to be less frequent (although underreporting in clinical trials is probable), but information on their management is highly relevant given that they can persist longer than other irAEs. Their management consists of anti-inflammatory treatment including glucocorticoids, synthetic and biologic immunomodulatory/immunosuppressive drugs, symptomatic therapies as well as holding or, rarely, discontinuation of immune checkpoint inhibitors. Here, we summarize the management of rheumatic/systemic irAEs based on data from clinical trials but mainly from published case reports and series, contextualize them and propose perspectives for their treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.